Fireside Chat: Perspectives on Big Pharma Acquisitions and Partnering

Date(s) - 06/12/18
4:30 pm - 6:30 pm

Rosalind Franklin University

Hosted by
SmartHealth Activator

Fireside Chat: Perspectives on Big Pharma Acquisitions and Partnering

Tue, June 12, 2018 4:30 PM – 6:30 PM

BioPathways is a monthly event series, featuring prominent bioentrepreneurs, biotech executives and biotech venture capitalists in a fireside chat. We will also feature a guest biotech startup in a quick pitch. This month we are featuring Catherine Sazdanoff, Chief Business Officer, Strate Oncology, Inc.

Catherine is a consultant and board member with extensive global healthcare experience. She is an independent director and Audit Committee member of the Board of Directors of Meridian Bioscience, Inc., a public diagnostics and life sciences company (NASDAQ: VIVO), and serves on the Advisory Board of Neurocern, Inc., a private dementia management system company. She is Business Advisor at Strata Oncology, Inc., a private precision oncology company, where she consults in corporate strategy and business development, marketing, public relations, legal and IP functions.

Catherine also supports community development and education, by mentoring healthcare startups at Chicago Innovation Mentors @ MATTER and Springboard Enterprises Life Sciences Advisory Council; she’s a board-readiness mentor for Women in Bio, and she serves on the Jobs Committee at Cristo Rey St. Martin College Prep School. Catherine is a lecturer in the Business of Biotechnology program at the University of Chicago Graham School and teaches advanced life sciences licensing with the Practicing Law Institute.

Starting as a litigator in Chicago, Catherine joined Abbott Laboratories in 1984 and moved through commercial and transactional legal roles, crossed into marketing, and then led pharmaceutical business development. She was sought after in high-risk and transformational matters, for example, Abbott’s $7B acquisition of Knoll Laboratories in 2001, adding global presence and assets including megablockbuster Humira®; and avoiding bet-the-company penalties such as exclusion from federal business and a $9B punitive damages award by successfully managing infant formula antitrust litigation. With her dual background, she also designed and managed Abbott’s global ethics and compliance program, including business operations, risk advisory and internal investigations.

Catherine moved to Takeda Pharmaceuticals in 2006, where she held various global VP roles in business development, corporate development, and finance, supporting Takeda’s globalization plans. She acquired Millennium Pharmaceuticals for $8B in 2008, then led the $13B acquisition of Nycomed S.A. in 2011, (significantly increasing Takeda’s revenue, EPS, and global footprint. She ran Nycomed BD integration while building and managing global R&D business development across multiple therapeutic areas including CNS, cardiovascular, metabolic, GI, renal, vaccines, respiratory and immunology. Catherine also led post-integration global restructuring, achieving recurring savings of >$500 MM.

Catherine has a B.A. in English from the University of Notre Dame (where, as a fencer, she was one of the first varsity-letter women in the history of the university), and a J.D. from Northwestern University School of Law. She is married with two children.